Menu Search
Equities

Cellectis SA

ALCLS:PAR

Cellectis SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)2.44
  • Today's Change-0.015 / -0.61%
  • Shares traded45.29k
  • 1 Year change+38.59%
  • Beta2.2962
Data delayed at least 15 minutes, as of Apr 30 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cellectis SA had revenues fall -33.35% from 38.60m to 25.73m, though the company grew net income from a loss of 114.20m to a smaller loss of 106.14m.
Gross margin--
Net profit margin-272.10%
Operating margin-224.91%
Return on assets-27.15%
Return on equity-55.73%
Return on investment-34.66%
More ▼

Cash flow in USDView more

In 2022, cash reserves at Cellectis SA fell by 92.42m. Cash Flow from Financing totalled 1.15m or 4.45% of revenues. In addition the company used 87.44m for operations while cash used for investing totalled 2.76m.
Cash flow per share-0.6728
Price/Cash flow per share--
Book value per share1.28
Tangible book value per share1.27
More ▼

Balance sheet in USDView more

Cellectis SA has a Debt to Total Capital ratio of 55.59%, a lower figure than the previous year's 57.30%.
Current ratio2.20
Quick ratio--
Total debt/total equity1.25
Total debt/total capital0.5559
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.